Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Kei EndoKeisuke KakisakaTamami AbeKenji YusaIppeki NakayaTakuya WatanabeHiroaki AbeAkiko SuzukiYuichi YoshidaTakayoshi OikawaAkio MiyasakaHidekatsu KurodaTakayuki MatsumotoPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
The present study demonstrated that GS is a sensitive marker for detecting a subclinical decline in the general condition and is therefore a potential predictor of the outcome of u-HCC patients treated with atezolizumab plus bevacizumab.